Clinical Trial Results:
Glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the general ward
Summary
|
|
EudraCT number |
2015-003669-27 |
Trial protocol |
AT |
Global end of trial date |
12 Oct 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Jan 2022
|
First version publication date |
11 Jan 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GlucoTab_U300
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Diabetology
|
||
Sponsor organisation address |
Auenbruggerplatz 15, Graz, Austria, 8010
|
||
Public contact |
Julia Mader, Medical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology, 43 31638580254, julia.mader@medunigraz.at
|
||
Scientific contact |
Julia Mader, Medical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology, +43 31638512383, julia.mader@medunigraz.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 May 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
12 Oct 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Oct 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To investigate the efficacy of the GlucoTab system for glycemic management using insulin glargine U300 in non-critically ill patients with type 2 diabetes at the general ward
|
||
Protection of trial subjects |
This study was conducted in full accordance with the principles of the “Declaration of Helsinki” (as amended in Tokyo, Venice, Hong Kong, Somerset West, and Edinburgh) and with the laws and regulations of the respective European countries.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Jun 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 30
|
||
Worldwide total number of subjects |
30
|
||
EEA total number of subjects |
30
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
21
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
It was the responsibility of the investigator to obtain oral and written informed consent prior to any study-related procedures. In obtaining and documenting informed consent, the investigator complied with applicable regulatory documents and adhered to the ICH GCP guideline and to the requirements in the Declaration of Helsinki. | ||||||
Pre-assignment
|
|||||||
Screening details |
This study included patients with type 2 diabetes mellitus or newly diagnosed hyperglycemia, both male and female, treated initially with oral agents, non-insulin injected antidiabetic medicine, insulin, diet or any combination of the four, and who were hospitalized for any condition at the Medical University of Graz. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
GlucoTab U300 | ||||||
Arm description |
.Glinide, sulfonylureas and glitazones were stopped. Metformin, SGLT2-inhibitors, GLP-1 analoga and DPP-4-inhibitors were continued according local standard procedures. Insulin therapy was adjusted according to the GlucoTab® system with incorporated software algorithm. Participants were treated with the GlucoTab® and its REACTION-Algorithm for basal bolus therapy using insulin glargine U300 and insulin glulisine. The algorithm had been tested previously using insulin glargine and had shown to safely establish glycemic control. Insulin therapy prescription for every following 24 hours was suggested once daily by the GlucoTab® system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the GlucoTab® system is to maintain fasting and pre-meal glucose concentrations between 70-140 mg/dL. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Toujeo 300 Einheiten/ml-Injektionslösung in einem Fertigpen
|
||||||
Investigational medicinal product code |
ATC-Code: A10A E04
|
||||||
Other name |
Toujeo, Sanofi-Aventis (insuline glargine U300)
|
||||||
Pharmaceutical forms |
Solution for injection in pre-filled pen
|
||||||
Routes of administration |
Subcutaneous use
|
||||||
Dosage and administration details |
According to GlucoTab®, insulin therapy was initiated at a daily dose of 0.5 units/kg. Half of this dose was administered as long acting once daily (glargine U300) and the other half as short acting insulin (glulisine) before meals. A bedtime glucose >180 mg/dL was not corrected by GlucoTab®. The initial total daily dose was reduced to 0.3 units/kg in patients ≥70 years of age and/or serum creatinine ≥ 2.0 mg/dL. In case the patient was already on insulin therapy it was possible to pre-set the doses manually.
|
||||||
Investigational medicinal product name |
Apidra Solostar 100 Einheiten/ml-Injektionslösung in einem Fertigpen
|
||||||
Investigational medicinal product code |
A10A
|
||||||
Other name |
Apidra, Sanofi Aventis (Insulin glulisine)
|
||||||
Pharmaceutical forms |
Solution for injection in pre-filled pen
|
||||||
Routes of administration |
Subcutaneous use
|
||||||
Dosage and administration details |
According to GlucoTab®, insulin therapy was initiated at a daily dose of 0.5 units/kg. Half of this dose was administered as long acting once daily (glargine U300) and the other half as short acting insulin (glulisine) before meals. A bedtime glucose >180 mg/dL was not corrected by GlucoTab®. The initial total daily dose was reduced to 0.3 units/kg in patients ≥70 years of age and/or serum creatinine ≥ 2.0 mg/dL. In case the patient was already on insulin therapy it was possible to pre-set the doses manually.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GlucoTab U300
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
.Glinide, sulfonylureas and glitazones were stopped. Metformin, SGLT2-inhibitors, GLP-1 analoga and DPP-4-inhibitors were continued according local standard procedures. Insulin therapy was adjusted according to the GlucoTab® system with incorporated software algorithm. Participants were treated with the GlucoTab® and its REACTION-Algorithm for basal bolus therapy using insulin glargine U300 and insulin glulisine. The algorithm had been tested previously using insulin glargine and had shown to safely establish glycemic control. Insulin therapy prescription for every following 24 hours was suggested once daily by the GlucoTab® system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the GlucoTab® system is to maintain fasting and pre-meal glucose concentrations between 70-140 mg/dL. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
GlucoTab U300
|
||
Reporting group description |
.Glinide, sulfonylureas and glitazones were stopped. Metformin, SGLT2-inhibitors, GLP-1 analoga and DPP-4-inhibitors were continued according local standard procedures. Insulin therapy was adjusted according to the GlucoTab® system with incorporated software algorithm. Participants were treated with the GlucoTab® and its REACTION-Algorithm for basal bolus therapy using insulin glargine U300 and insulin glulisine. The algorithm had been tested previously using insulin glargine and had shown to safely establish glycemic control. Insulin therapy prescription for every following 24 hours was suggested once daily by the GlucoTab® system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the GlucoTab® system is to maintain fasting and pre-meal glucose concentrations between 70-140 mg/dL. |
|
|||||||||
End point title |
Mean percentage of blood glucose measurements restricted to blood glucose values measured ≥ 24 hours after start of therapy in the target range 70 to 140 mg/dL [1] | ||||||||
End point description |
|||||||||
End point type |
Primary
|
||||||||
End point timeframe |
whole study duration ≥ 24 hours after start of therapy
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: All parameters were analysed by descriptive and explorative statistical methods. No hypotheses were tested. The primary endpoint was "the mean percentage of blood glucose measurements lying in the target range from 70 to 140 mg/dL." |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Overall mean BG values | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
whole study duration
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
BG measurements in different ranges (percentage) | ||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
whole study duration
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Missed BG measurements and insulin injections | ||||||||||||||
End point description |
|||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
whole study duration except first and last study day
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||
End point title |
Overall mean numbers | ||||||||||||||||||||||||||||||||
End point description |
Suggested dose: Insulin dose suggested by the first step of the algorithm before applying the sliding-scale correction
Correction dose: Insulin dose added (or subtracted) by the second step of the algorithm
Calculated dose: Insulin dose finally calculated by the algorithm
Dose correction by user: Difference between calculated insulin by the algorithm and insulin dose finally administered
Injected dose: Insulin dose finally administered
|
||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||
End point timeframe |
whole study duration
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Basal and bolus insulin dose corrections (percentage) | ||||||||||||||||||||||
End point description |
|||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
whole study duration except day 1
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Health-care professional adherence to suggested insulin doses | ||||||||||||||
End point description |
|||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
whole study duration after day 1
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were assessed during the whole study duration
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
23
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
GlucoTab U300
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
.Glinide, sulfonylureas and glitazones were stopped. Metformin, SGLT2-inhibitors, GLP-1 analoga and DPP-4-inhibitors were continued according local standard procedures. Insulin therapy was adjusted according to the GlucoTab® system with incorporated software algorithm. Participants were treated with the GlucoTab® and its REACTION-Algorithm for basal bolus therapy using insulin glargine U300 and insulin glulisine. The algorithm had been tested previously using insulin glargine and had shown to safely establish glycemic control. Insulin therapy prescription for every following 24 hours was suggested once daily by the GlucoTab® system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the GlucoTab® system is to maintain fasting and pre-meal glucose concentrations between 70-140 mg/dL. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
limited number of patients; no randomization; study was only performed at one clinical ward |